Ngl Fine Chem Ltd Share Price

Overview

Ngl Fine Chem Ltd share price is currently ₹2,838.52, up by ₹69.27 (2.5%) from its previous closing price of ₹2,769.25. The share price has declined -9.86% over the past month and gained 122.63% over the past year. The stock's 52-week low and high are ₹1,254.34 and ₹3,550.55, respectively. Ngl Fine Chem Ltd has a market capitalisation of ₹ 1,820.00 Cr. The share price was last updated on 26 Aug 2026, 03:29 PM IST.

Ngl Fine Chem Ltd
Ngl Fine Chem Ltd
NGLFINE
 0.00
 69.27
2.50%
Healthcare
 0.00(%)1D

Updated: 26 Aug 2026, 03:29:34 pm IST

Market Data

Open Price

 2,753.04

Prev. Close

 2,769.25
 2,753.04

Day Low

 2,845.79

Day High

 1,254.34

52 Week Low

 3,550.55

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

30.66

Sector PE

42.03

PB Ratio

5.33

Sector PB

5.83

EPS

92.59

Dividend Yield

0.08

Today's Volume

3.313 K

5 Day Avg. Volume

7.791 K

PEG Ratio

0.24

Market Cap.

₹ 1,820.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 35% at ₹1.75/Share
18-Aug-202618-Aug-2026
DividendsFinal Dividend of 35% at ₹1.75/Share
12-Aug-202512-Aug-2025

Mutual Fund Ownership

Mutual Fund Holder
Jul 25
Shares held
Aug 25
Shares held
Motilal Oswal BSE Healthcare ETF39
40
(2.56%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth23
23
no change

About Ngl Fine Chem Ltd 👋

NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Adarsh Nimborkar (SEBI IA)

Adarsh Nimborkar (SEBI IA)

18 Aug • 9:08 AM · SEBI-Registered Analyst

NGL Fine-Chem Ltd – Company Analysis

NGLFINE
NGL Fine-Chem Ltd is a niche pharmaceutical company engaged in manufacturing active pharmaceutical ingredients, veterinary pharmaceuticals and human healthcare products. Its business is focused on specialized products rather than mass-market formulations, giving it exposure to the growing animal-health and pharmaceutical markets. The company operates as a single pharmaceutical segment and has established manufacturing capabilities and regulatory approvals that create entry barriers in its chosen markets. Profitability improved dramatically alongside revenue growth. In Q4 FY26, consolidated revenue increased 61.4% year-on-year to about ₹151.7 crore, while operating profit jumped nearly 239% and net profit surged to ₹13.5 crore from just ₹0.5 crore in the corresponding quarter. For FY26, the company reported total revenue of approximately ₹516 crore, compared with ₹377 crore in FY25. Looking ahead, NGL Fine-Chem can benefit from rising demand for veterinary healthcare, pharmaceutical ingredients and specialized animal-health products. Its niche positioning and established manufacturing capabilities provide a reasonable competitive advantage, while continued capacity utilization and product expansion could support earnings growth. However, investors should monitor regulatory compliance, raw-material costs, customer concentration, export opportunities and the sustainability of the recent margin expansion. The stock has also become expensive after its strong rerating, so valuation is now an important consideration. Overall, NGL Fine-Chem has delivered a meaningful FY26 turnaround with strong revenue and profit momentum, but the investment case increasingly depends on sustaining this improved profitability rather than merely repeating one exceptionally strong quarter.

See More
Sarathi Research

Sarathi Research

25 Oct • 11:09 PM · SEBI-Registered Analyst

NGL Fine Chem – A Hidden Gem in Specialty Pharma

NGLFINE
NGL Fine Chem is a niche pharmaceutical company specializing in veterinary and animal health products. It has been expanding its export footprint across Latin America and Africa, contributing significantly to revenue growth. The company has improved its operating margins through better efficiency and increased investment in R&D. With a strong base in both specialty chemicals and pharma APIs, NGL Fine Chem is well-positioned to capture future opportunities in the high-margin animal healthcare segment. This small-cap stock is slowly emerging as a promising long-term growth story Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile.

See More
Sohrab Shaikh (SEBI RA)

Sohrab Shaikh (SEBI RA)

11 Aug • 10:47 PM · SEBI-Registered Analyst

Companies having ex dividend date on 12.08.25

Final Dividend 1. Arvind Fashions Rs. 1.6 per share 2. Axtel Industries Rs. 6 per share 3. Dwarikesh Sugar Industries Rs. 0.5 per share 4. Grasim Industries Rs. 10 per share 5. HG Infra Rs. 2 per share 6. ICICI Bank Rs. 11 per share 7. India Pesticides Rs. 0.75 per share 8. KIFS Financial Rs. 1.5 per share 9. NGL Fine Chem Rs. 1.75 per share 10. Rites Interim Dividend Rs. 1.3 per share

ICICIBANK

See More
SFP RESEARCH

SFP RESEARCH

7 May • 9:03 AM · SEBI-Registered Analyst

NGL Fine-Chem

NGL Fine-Chem is a rare play in India’s listed veterinary pharmaceuticals space. It manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for animal healthcare—a niche, underpenetrated industry with low competition. While most pharma investors focus on human generics, NGL has carved a moat in veterinary drugs, exporting to over 50 countries. What’s unique is that NGL focuses on backward integration and runs R&D in-house, which helps it maintain high margins despite being a small-cap. It is also one of the few Indian companies approved by international regulators specifically for veterinary products. Despite global headwinds, the company reported over ₹225 crore in revenue in FY24 and maintains a ~20% net profit margin. It has recently expanded its Ankleshwar plant to boost production and is entering new therapeutic categories like antiparasitics and feed additives. With global pet care and livestock markets growing steadily, NGL is positioned well for secular growth.

See More
Ashish Kumar

Ashish Kumar

15 Feb • 1:27 PM · SEBI-Registered Analyst

Small-Cap Stocks Take a Hit as BSE Index Dips

The BSE Small-cap index has seen a significant decline, dropping 9.5 percent. This downturn has affected a large number of stocks, with over 450 experiencing losses between 10 and 41 percent. Several companies have been particularly hard hit, with shares falling between 25 and 41 percent. These include NGL Fine Chem,

NATCOPHARM
, Excel Industries, Orchid Pharma, WPIL, Tilaknagar Industries, Banco Products (India), Senco Gold, Suyog Telematics, Concord Biotech, Zaggle Prepaid Ocean Services,
PRINCEPIPE
Pipes & Fittings, Gensol Engineering, Lincoln Pharmaceuticals, and Suraj Estate Developers. Despite the overall negative trend, some stocks have managed to buck the trend and post gains. Among these are Garware Hi-Tech Films, Kennametal India, Godfrey Phillips India, Vimta Labs, Indo Count Industries, TCPL Packaging, and Redington. This downturn in the small-cap segment comes as the BSE Small-cap index has slipped 22% from its record high. Investors are likely keeping a close watch on market trends to assess the potential for further fluctuations.

See More

News & Events

Frequently Asked Questions

What is the share price of Ngl Fine Chem Ltd?

What is the market cap of Ngl Fine Chem Ltd?

Should I buy Ngl Fine Chem Ltd stock now?

What is the 52 week high and low of Ngl Fine Chem Ltd?

Is the Ngl Fine Chem Ltd stock good to buy?

Is Ngl Fine Chem Ltd a good buy for the long term?

Is Ngl Fine Chem Ltd overvalued or undervalued?

What is the PE and PB ratio of Ngl Fine Chem Ltd?

Start Now